GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Stryker Corporation (SYK) [hlAlert]

Rating:
Outperform
SYK
up 61.41 %

Stryker Corporation (SYK) rated Outperform with price target $47 by Leerink Swann

Posted on: Monday,  Dec 22, 2008  8:25 AM ET by Leerink Swann

Leerink Swann rated Outperform Stryker Corporation (NYSE: SYK) on 12/22/2008. Previously Leerink Swann rated Outperform Stryker Corporation (NYSE: SYK) on
06/23/2008., when the stock price was $62.62. Since then, Stryker Corporation has gained 61.42% as of 01/08/2016's recent price of $101.08.
If you would have followed the previous Leerink Swann 's recommendation on SYK, you would have gained 61.41% of your investment in 2755 days.

Stryker Corporation (Stryker) is a medical technology company with a range of products in orthopaedics and a presence in other medical specialties. The Company's products include implants used in joint replacement, trauma, craniomaxillofacial and spinal surgeries; biologics; surgical, neurologic, ear, nose and throat and interventional pain equipment; endoscopic, surgical navigation, communications and digital imaging systems; as well as patient handling and emergency medical equipment. The Company operates in two business segments: Orthopaedic Implants and MedSurg Equipment. The Orthopaedic Implants segment sells orthopaedic reconstructive (hip, knee and shoulder), trauma, craniomaxillofacial and spinal implant systems; bone cement; and the bone growth factor OP-1. The MedSurg Equipment segment sells surgical equipment; surgical navigation systems; endoscopic, communications and digital imaging systems; as well as patient handling and emergency medical equipment.

Leerink Swann Equity Research provides unique perspectives and agenda-setting healthcare recommendations for investors. Supported by industry-based intelligence and thorough market examination, our proprietary research enables our clients to make well-informed healthcare investment decisions. Our investment perspectives are driven by proprietary insights from MEDACorp. MEDACorp's more than 25,000 network professionals work with new and/or development-stage pharmaceuticals, medical devices and biotherapeutics on a daily basis. MEDACorp's extensive knowledge of products and research enables Leerink Swann to provide growth-focused clients an expertise earned through experience.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
12/22/2008 8:25 AM Buy
None
39.69 47.00
as of 12/24/2008
1 Week up  1.55 %
1 Month up  17.25 %
3 Months down  -2.30 %
1 YTD down  -2.92 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
12/1/2008 8:25 AM Buy
None
38.36 49.00
6/23/2008 8:25 AM Buy
None
62.62 76.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy